Bcr-Abl fusion gene drives the onset and development of CML, whereas the oncoprotein BCR-ABL with increased tyrosine kinase activity serves as a target for TKI treatment [33, 34]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.